Logistics of Radioimmunotherapy with Yttrium 90 Ibritumomab Tiuxetan (Zevalin)

A. Michael Zimmer*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

8 Scopus citations


Radioimmunotherapy is a promising new therapeutic option for the treatment of B-cell non-Hodgkin's lymphoma. Several monoclonal antibody and radionuclide conjugates, including 1-131 tositumomab and Y-90 ibritumomab, have been investigated in clinical trials. Yttrium 90 ibritumomab tiuxetan (Zevalin; Biogen Idec Inc, Cambridge, MA) is indicated for the treatment of patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma, including patients with rituximab-refractory follicular non-Hodgkin's lymphoma. The ibritumomab tiuxetan regimen requires coordination of a multidisciplinary team on which the nuclear medicine physician (or radiation oncologist) plays a major role. The nuclear medicine physician (or radiation oncologist) is responsible for overseeing the administration of the radioimmunoconjugates and for interpreting the imaging scans to determine the expected or altered biodistribution of the radioimmunoconjugate.

Original languageEnglish (US)
Pages (from-to)14-19
Number of pages6
JournalSeminars in Nuclear Medicine
Issue number1 SUPPL.1
StatePublished - Jan 2004

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'Logistics of Radioimmunotherapy with Yttrium 90 Ibritumomab Tiuxetan (Zevalin)'. Together they form a unique fingerprint.

Cite this